Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYT107 for Lymphopenic COVID-19 Patients
NCT04442178Phase 2Terminated
- Sponsor
- RevImmune
- Start
- Sep 2020
- Primary completion
- Mar 2022
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of efineptakin alfa in coronavirus disease 2019 (COVID-19), sponsored by RevImmune. Started Sep 2020; status: terminated.
02
Drugs
efineptakin alfa
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04442178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04442178.